Ampulla of Vater adenocarcinoma in a BRCA2 germline mutation carrier

[1] Romiti A., Barucca V., Zullo A., Sarcina I., Di Rocco R., Et al., Tumors of ampulla of Vater: A case series and review of chemotherapy options, World J Gastrointest Oncol, 4, pp. 60-67, (2012)

[2] Dagan E., Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer, Genetic Testing, 12, 2, pp. 267-271, (2008)

[3] Ferrone C.R., Levine D.A., Tang L.H., Allen P.J., Jarnagin W., Et al., BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, pp. 433-438, (2009)

[4] Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Grutzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K., BRCA2 germline mutations in familial pancreatic carcinoma, Journal of the National Cancer Institute, 95, 3, pp. 214-221, (2003)

[5] Lowery M., Shah M.A., Smyth E., Epstein A., Segal A., Et al., A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma, Journal of Gastrointestinal Cancer, 42, pp. 160-164, (2011)

[6] Sonnenblick A., Kadouri L., Appelbaum L., Peretz T., Sagi M., Et al., Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy, Cancer Biology & Therapy, 12, pp. 165-168, (2011)

[7] Riall T.S., Cameron J.L., Lillemoe K.D., Winter J.M., Campbell K.A., Hruban R.H., Chang D., Yeo C.J., Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up, Surgery, 140, 5, pp. 764-772, (2006)

[8] Lee J.H., Whittington R., Williams N.N., Berry M.F., Vaughn D.J., Haller D.G., Rosato E.F., Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas, International Journal of Radiation Oncology Biology Physics, 47, 4, pp. 945-953, (2000)

[9] Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, pp. 1273-1281, (2010)

[10] Kim R., Byer J., Saif M.W., BRCA and pancreatic cancer: Selection of chemotherapy, JOP: Journal of the Pancreas, 13, pp. 180-181, (2012)

[1] Romiti A., Barucca V., Zullo A., Sarcina I., Di Rocco R., Et al., Tumors of ampulla of Vater: A case series and review of chemotherapy options, World J Gastrointest Oncol, 4, pp. 60-67, (2012)

[2] Dagan E., Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer, Genetic Testing, 12, 2, pp. 267-271, (2008)

[3] Ferrone C.R., Levine D.A., Tang L.H., Allen P.J., Jarnagin W., Et al., BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, pp. 433-438, (2009)

[4] Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Grutzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K., BRCA2 germline mutations in familial pancreatic carcinoma, Journal of the National Cancer Institute, 95, 3, pp. 214-221, (2003)

[5] Lowery M., Shah M.A., Smyth E., Epstein A., Segal A., Et al., A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma, Journal of Gastrointestinal Cancer, 42, pp. 160-164, (2011)

[6] Sonnenblick A., Kadouri L., Appelbaum L., Peretz T., Sagi M., Et al., Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy, Cancer Biology & Therapy, 12, pp. 165-168, (2011)

[7] Riall T.S., Cameron J.L., Lillemoe K.D., Winter J.M., Campbell K.A., Hruban R.H., Chang D., Yeo C.J., Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up, Surgery, 140, 5, pp. 764-772, (2006)

[8] Lee J.H., Whittington R., Williams N.N., Berry M.F., Vaughn D.J., Haller D.G., Rosato E.F., Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas, International Journal of Radiation Oncology Biology Physics, 47, 4, pp. 945-953, (2000)

[9] Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, pp. 1273-1281, (2010)

[10] Kim R., Byer J., Saif M.W., BRCA and pancreatic cancer: Selection of chemotherapy, JOP: Journal of the Pancreas, 13, pp. 180-181, (2012)